Marvel Biosciences Reports Promising Preclinical Results from Autism Study

Marvel Biosciences Corp. (OTCQB: MBCOF) has reported promising interim results from its study on MB-204, a new treatment for autism. The study, being conducted by the iBrain Institute in Tours, France, has demonstrated that a single oral dose of MB-204 can restore social interaction behaviors to normal levels in autism model mice, with notable improvements in cognitive function. Marvel believes this advancement could signify a pivotal shift in autism therapy.

“The interim data we’ve seen is not just promising; it could offer a totally novel approach to treating autism,” said Dr Julie Le Merrer, one of the study’s investigators. “The capacity of MB-204 to normalize behavior in animal models of autism supports our theory about the A2a receptor’s influence on social interactivity. We’re eager to validate these results with further testing and robust statistical analysis, which is already underway and expected to conclude in the coming months.”

Highlights

Marvel’s study investigated the effects of MB-204 on socialization and cognition in a mouse model of autism.

MB-204 fully restored social deficits at a single oral dose as low as 1 mg/kg but also enhanced certain social behaviors beyond normal levels at a 2.5 mg/kg oral dose. These unexpected findings indicate a substantial potential of MB-204 to address the core symptoms of autism.

Autism is an underserved medical condition that affects approximately 1 in 36 children. It is characterized by difficulty with communication, difficulty with social interactions, obsessive interests, and repetitive behaviors.

The social impact cost of autism in the US is expected to exceed $450 billion by 2025.

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Share This Article

 

About the Author

Marvel Biosciences Reports Promising Preclinical Results from Autism Study

Catie Corcoran

Biotech Editor